Genetic control of the immune response to HIV type 1 envelope glycoprotein 120 in mice: Effects of MHC and transgenic human CD4

AIDS Research and Human Retroviruses

Volumn 14, Issue 10, 1998, Pages 893-900

  Berkower, Ira ^a,b   Bridgewater, Jennifer ^a  

^a Center for Biologics   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; GLYCOPROTEIN GP 120;

ACTIVE IMMUNIZATION; ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ANTIBODY SPECIFICITY; ARTICLE; GENE EXPRESSION REGULATION; HOST RESISTANCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOREGULATION; INFECTION RESISTANCE; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; TRANSGENE; VACCINATION; VIRUS INFECTIVITY;

EID: 0032504019     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.1998.14.893     Document Type: Article

References (54)

1. Chou MJ, Lee TH, Hatzakis A, Mandalaki T, McLane MF, and Essex M: Antibody responses in early human immunodeficiency virus type 1 infection in hemophiliacs. J Infect Dis 1988;157: 805-811.
2. Berkower I, Smith GE, Giri C, and Murphy D: HIV-1 inactivation by antibodies: Predominance of a group-specific epitope that persists despite genetic variation. J Exp Med 1989;170:1681-1695.
3. Redfield RR, Birx DL, Ketter N, Tramont E, Polonis V, et al.: A phase I evaluation of the safety and immunogenicity of vaccination with recombinant gp160 in patients with early human immunodeficiency virus infection. N Engl J Med 1991;324:1677-1684.
4. Belshe RB, Graham BS, Keefer MC, Gorse GJ, Wright P, Dolin R, Matthews T, et al.: Neutralizing antibodies to HIV-1 in seronegative volunteers immunized with recombinant gp120 from the MN strain of HIV-1. JAMA 1994;272:475-480.
5. Schwartz DH, Gorse G, Clements ML, Belshe R, Izu A, Duliege A-M, Berman P, Twaddell T, Stablein D, Sposto R, Siliciano R, and Matthews T: Induction of HIV-1 neutralizing and syncytium-inhibiting antibodies in uninfected recipients of HIV-IIIB rgp120 subunit vaccine. Lancet 1993;342:69-73.
6. Graham BS, Keefer MC, McElrath J, Gorse GJ, Schwartz DH, Weinhold K, Matthews TJ, Esterlitz JR, Sinangil F, and Fast PE: Safety and immunogenicity of a candidate HIV-1 vaccine in healthy adults: Recombinant glycoprotein (rgp) gp120. Ann Intern Med 1996;125:270-279.
7. SF2 gp120 subunit vaccine combined with MF59 adjuvant with or without muramyl tripeptide dipalmitoyl phosphatidylethanolamine in non-HIV-infected human volunteers. J Infect Dis 1994;170: 1288-1291.
8. Maddon P, Dalgleish AG, McDougal JS, Clapham PN, Weiss RA, and Axel R: The T4 gene encodes the AIDS virus receptor and is expressed in the immune system and the brain. Cell 1986;47: 333-348.
9. McClure MD, Sattentau QJ, Beverley PC, Hearn JP, Fitzgerald AK, Zuckemian AJ, and Weiss RA: HIV infection of primate lymphocytes and conservation of the CD4 receptor. Nature (London) 1987;330:487-489.
10. Feng Y, Broder CC, Kennedy PE, and Berger EA: HIV-1 entry cofactor: Functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science 1996;272:872-877.
11. Deng HK, Liu R, Ellmeier W, Choe S, et al.: Identification of a major coreceptor for primary isolates of HIV-1. Nature (London) 1996;381:661-666.
12. Dragic T, Litwin V, Allaway GP, et al.: HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5. Nature (London) 1996;381:667-673.
13. Kowalski M, Potz J, Basiripour L, Dorfman T, Goh WC, Terwilliger E, Dayton A, Rosen C, Haseltine W, and Sodroski J: Functional regions of the envelope glycoprotein of human immunodeficiency virus type 1. Science 1987;237:1351-1355.
14. Sattentau QJ and Moore JP: Conformational changes induced in the human immunodeficiency virus envelope glycoprotein by soluble CD4 binding. J Exp Med 1991;174:407-415.
15. Chan DC, Fass D, Berger JM, and Kim PS: Core structure of gp41 from the HIV envelope glycoprotein. Cell 1997;89:263-273.
16. Berkower I, Mostowski H, Bull TE, and Murphy D: CD4-IgG binding threshold for inactivation of human immunodeficiency virus type 1. J Infect Dis 1996;173:863-869.
17. Steimer KS, Scandella CJ, Skiles PV, and Haigwood NL: Neutralization of divergent HIV-1 isolates by conformation-dependent human antibodies to gp120. Science 1991;254:105-108.
18. Kang C-Y, Nara P, Chamat S, et al.: Evidence for non-V3-specific neutralizing antibodies that interfere with gp120/CD4 binding in human immunodeficiency virus 1-infected humans. Proc Natl Acad Sci USA 1991;88:6171-6175.
19. Berkower I, Murphy D, Smith CC, and Smith GE: A predominant group specific neutralizing epitope of HIV-1 maps to residues 342-511 of the envelope glycoprotein gp120. J Virol 1991;65: 5983-5990.
20. Thali M, Olshevsky U, Furman C, Gabuzda D, Posner M, and Sodroski J: Characterization of a discontinuous human immunodeficiency virus type 1 gp120 epitope recognized by a broadly reactive neutralizing human monoclonal antibody. J Virol 1991;65: 6188-6193.
21. Tilley SA, Honnen WJ, Racho ME, Hilgartner M, and Pinter A: A human monoclonal antibody against the CD4-binding site of HIV-1 gp120 exhibits potent, broadly neutralizing activity. Inst Pasteur Res Virol 1991;142:247-259.
22. Pollard ST, Rosa MD, Rosa JJ, and Wiley DC: Truncated variants of gp120 bind CD4 with high affinity and suggest a minimum CD4 binding region. EMBO J 1992;11:585-591.
23. Blum MD, Wong GT, Higgins KM, Sunshine MJ, and Lacy E: Reconstitution of the subclass-specific expression of CD4 in thymocytes and peripheral T cells of transgenic mice: Identification of a human CD4. enhancer. J Exp Med 1993;177:1343-1358.
24. Berzofsky JA: Ir genes: Antigen-specific genetic regulation of the immune response. In: The Antigens (M. Sela, ed.), Vol. 7. Academic Press, New York, 1987, pp. 1-146.
25. Rammensee H-G, Friede T, and Stevanovic S: MHC ligands and peptide motifs: First listing. Immunogenetics 1995;41: 178-228.
26. Berzofsky JA and Berkower IJ: Novel approaches to peptide and engineered protein vaccines for HIV using defined epitopes; advances in 1994-95. AIDS 1995;9(Suppl. A):S143-S157.
27. Cochran MA, Ericson BL, Knell JD, and Smith GE: Use of baculovirus recombinants as a general method for the production of subunit vaccines. In: Vaccines 87: Modern Approaches to New Vaccines: Prevention of AIDS and Other Viral, Bacterial, and Parasitic Diseases. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, 1987, pp. 384-388.
28. Scandella CJ, Kilpatrick J, Lidster W, Parker C, Moore JP, Moore GK, Mann KA, Brown P, Coates S, Chapman B, Masiarz FR, Steimer KS, and Haigwood NL: Nonaffinity purification of recombinant gp120 for use in AIDS vaccine development. Aids Res Hum Retroviruses 1993;9:1233-1244.
29. Berkower I and Murphy D: Enzymatic labeling of biologically active envelope glycoprotein gp120 of HIV-1. Biochem Biophys Res Commun 1993;191:1055-1065.
30. Myers G, Rabson AB, Berzofsky JA, Smith TF, and Wong-Staal F: Human Retroviruses and AIDS: A Compilation and Analysis of Nucleic Acid and Amino Acid Sequences. Los Alamos National Laboratory, Los Alamos, New Mexico, 1992.
31. Leonard CK, Spellman MW, Riddle L, Harris RJ, Thomas JN, and Gregory TJ: Assignment of intrachain disulfide bonds and characterization of potential glycosylation sites of the type 1 recombinant human immunodeficiency virus envelope glycoprotein (gp120) expressed in Chinese hamster ovary cells. J Biol Chem 1990;265: 10373-10382.
32. Miyazawa M, Nishio J, and Chesebro B: Genetic control of T cell responsiveness to the Friend murine leukemia virus envelope antigen: Identification of class II loci of the H-2 as immune response genes. J Exp Med 1988;168:1587-1605.
33. Lilly F and Pincus T: Genetic control of murine viral leukemogenesis. Adv Cancer Res 1973;17:231-277.
34. Chesebro B, Miyazawa M, and Britt WJ: Host genetic control of spontaneous and induced immunity to Friend murine retrovirus infection. Annu Rev Immunol 1990;8:477-499.
35. Lonai P and Haran-Ghera N: Resistance genes to murine leukemia in the I immune response gene region of the H-2 complex. J Exp Med 1977;146:1164-1168.
36. Muhlbock O and Dux A: Histocompatibility genes (the H-2 complex) and susceptibility to mammary tumor virus in mice. J Natl Cancer Inst 1974;53:993-996.
37. Cease KB, Margalit H, Cornette JL, Putney SD, Robey WG, Ouyang C, Streicher HZ, et al.: Helper T cell antigenic site identification in the AIDS virus gp120 envelope protein and induction of immunity in mice to the native protein using a 16-residue synthetic peptide. Proc Natl Acad Sci USA 1987;84:4249-4253.
38. Hale PM, Cease KB, Houghten RA, Ouyang C, Putney S, Javaherian K, Margalit H, Comette JL, Spouge JL, DeLisi C, and Berzofsky JA: T cell multideterminant regions in the human immunodeficiency virus envelope: Toward overcoming the problem of major histocompatibility complex restriction. Int Immunol 1989;1:409-415.
39. Ahlers JD, Dunlop N, Pendleton CD, Newman M, Nara PL, and Berzofsky JA: Candidate HIV type 1 multideterminant cluster peptide-p18MN vaccine constructs elicit type 1 helper T cells, cytotoxic T cells and neutralizing antibody, all using the same adjuvant immunization. AIDS Res Hum Retroviruses 1996;12:259-272.
40. Korber BTM, Brander C, Walker BD, Koup R, Moore JP, Haynes BF, and Myers G: HIV Molecular Immunology Database 1995, Section II. Los Alamos National Laboratory, Los Alamos, New Mexico, 1995.
41. Clark EA and Ledbetter JA: How B and T cells talk to each other. Nature (London) 1994;367:425-428.
42. Dolin R, Graham BS, Greenberg SB, et al.: The safety and immunogenicity of a human immunodeficiency virus type 1 (HIV-1) recombinant gp160 candidate vaccine in humans. Ann Intern Med 1991;114:119-127.
43. Keefer MC, Graham BS, Belshe RB, Schwartz D, Corey L, Bolognesi DP, Stablein DM, Monterfiori DC, et al.: Studies of high doses of human immunodeficiency virus type 1 recombinant glycoprotein 160 candidate vaccine in HIV type 1-seronegative humans. AIDS Res 1994;10:1713-1723.
44. Clerici M, Stocks NI, Zajac RA, Boswell RN, Lucey DR, Via CS, and Shearer GM: Detection of three distinct patterns of T helper cell dysfunction in asymptomatic, human immunodeficiency virus-seropositive patients: Independence of CD4 cell numbers and clinical staging. J Clin Invest 1989;84:1892-1899.
45. Gorse GJ, Patel GB, Newman FK, Mandava M, and Belshe RB: Recombinant gp160 vaccination schedule and MHC HLA type as factors influencing cellular responses to HIV-1 envelope glycoprotein. Vaccine 1995;13:1170-1179.
46. Berman PW, Eastman DJ, Wilkes DM, Nakamura GR, Gregory TJ, Schwartz D, Gorse G, Belshe R, Clements ML, and Byrn RA: Comparison of the immune response to recombinant gp120 in humans and chimpanzees. AIDS 1994;8:591-601.
47. El-Amad Z, Murthy KK, Higgins K, Cobb EK, Haigwood NL, Levy JA, and Steimer KS: Resistance of chimpanzees immunized with recombinant gp120 SF2 to challenge by HIV-1 SF2. AIDS 1995;9:1313-1322.
48. Kahn JO, Steimer KS, Baenziger J, Duliege A-M, Feinberg M, Elbeik T, Chesney M, Murcar N, Chernoff D, and Sinangil F: Clinical, immunologic, and virologic observations related to human immunodeficiency virus (HIV) type 1 infection in a volunteer in an HIV-1 vaccine clinical trial. J Infect Dis 1995;171:1343-1347.
49. Milich DR, McLachlan A, Thornton GB, and Hughes JL: Antibody production to the nucleocapsid and envelope of the hepatitis B virus primed by a single synthetic T cell site. Nature (London) 1987;329:547-549.
50. Cole KS, Rowles JL, Jagerski BA, Murphey-Corb M, Unangst T, Clements JE, Robinson J, Wyand MS, Desrosiers RC, and Montelaro RC: Evolution of envelope-specific antibody responses in monkeys experimentally infected or immunized with simian immunodeficiency virus and its association with the development of protective immunity. J Virol 1997;71:5069-5079.
51. VanCott TC, Mascola JR, Kaminski RW, Kalyanaraman V, Hallberg PL, Burnett PR, Ulrich JT, Rechtman DJ, and Birx DL: Antibodies with specificity to native gp120 and neutralization activity against primary HIV-1 isolates elicited by immunization with oligomeric gp160. J Virol 1997;71:4319-4330.
52. Javaherian K, Langlois AJ, McDanal C, Ross KL, Eckler LI, Jellis CL, Profy AT, Rusche JR, Bolognesi DP, Putney SD, and Matthews TJ: Principal neutralizing domain of the human immunodeficiency virus type 1 envelope protein. Proc Natl Acad Sci USA 1989;86:6768-6772.
53. Madrenas J, Chau LA, Smith J, Bluestone JA, and Germain RN: The efficiency of CD4 recruitment to ligand-engaged TCR controls the agonist/partial agonist properties of peptide-MHC molecule ligands. J Exp Med 1997;185:219-229.
54. Wang Z-Q, Orlikowsky T, Dudhane A, et al.: Deletion of T lymphocytes in human CD4 transgenic mice induced by HIV-gp120 and gp120-specific antibodies from AIDS patients. Eur J Immunol 1994;24:1553-1557.